Illustrative image – not actual.Ind-Swift Laboratories Ltd (ISLL) has begun
commercial production at its new multi-purpose plant at Dera Bassi in Punjab.
The plant would be manufacturing four specialty bulk drugs– Pioglitazone,
Candesartan, Ramipril and Clopidogrel.
The unit has been set up at a cost of
Rs.6 crore comprising Rs.4 crore of term loans and Rs.2 crore of internal
accruals.
ISLL, a Chandigarh-based company
engaged in the manufacture of bulk drugs and intermediaries, is part of the
Rs.150 crore Ind-Swift group.
